Uncategorized
FDA sets Aug. 24 as PDUFA date for latanoprostene bunod
The FDA has set Aug. 24 for its decision on the new drug application for latanoprostene bunod, according to a press release from Bausch + Lomb and Nicox.Latanoprostene bunod ophthalmic solution 0.024% is a single-agent once-daily eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension. If approved, it will be the first nitric-oxide donating prostaglandin F2 alpha analog for ophthalmic use, the release said.